Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2000
12/14/2000WO2000074718A1 Immunotherapy of autoimmune disorders using antibodies which target b-cells
12/14/2000WO2000074700A2 Uses of ouabain and ouabain-like molecules in apoptosis related pathologies
12/14/2000WO2000074696A1 Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe
12/14/2000WO2000074691A1 Treatment of cutaneous leishmaniasis and other dermatological diseases mainly wounds (diabetic ulcers) by idogenos sanhory
12/14/2000WO2000074689A1 Unfermented gel fraction from psyllium seed husks
12/14/2000WO2000074687A1 Antisense modulation of b7 protein expression
12/14/2000WO2000074686A1 Modulators of methylation for control of bacterial virulence
12/14/2000WO2000074685A1 Oral preparations of etidronate disodium
12/14/2000WO2000074684A1 Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
12/14/2000WO2000074683A1 Antitumor effect potentiators
12/14/2000WO2000074682A1 Thrombin inhibitors
12/14/2000WO2000074681A1 Metalloprotease inhibitors
12/14/2000WO2000074680A1 The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder
12/14/2000WO2000074679A1 Substituted piperidines as melanocortin-4 receptor agonists
12/14/2000WO2000074678A1 Analgesics
12/14/2000WO2000074677A2 Improved pharmaceutical formulations
12/14/2000WO2000074676A1 Use of riluzole for the treatment of multiple sclerosis
12/14/2000WO2000074675A1 Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines
12/14/2000WO2000074672A1 Method and compositions for treating and preventing retinal damage
12/14/2000WO2000074671A1 Method and markers for prognosticating efficacy of anticancer agents
12/14/2000WO2000074670A1 USE OF VERAPAMIL AND VERAPAMIL DERIVATIVES FOR PRODUCING MEDICAMENTS WITH AN INHIBITING EFFECT ON β-GLUCURONIDASE IN HUMAN TISSUE
12/14/2000WO2000074669A1 Methods for improving the functional status of sperm
12/14/2000WO2000074668A1 Non-solid composition for local application
12/14/2000WO2000074667A2 Compositions active in telomere damage comprising a taxane and telomerase inhibitor
12/14/2000WO2000074666A2 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia
12/14/2000WO2000074665A2 New use of macrolide compounds for inducing chondrogenic differentiation
12/14/2000WO2000074664A2 Novel iron chelators and pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders
12/14/2000WO2000074663A2 Use of allicin for control of weight in mammals
12/14/2000WO2000074662A2 Arthritis treatment
12/14/2000WO2000074659A1 Morphine sulphate microgranules, method for preparing same and compositions containing same
12/14/2000WO2000074658A1 Use of drug-loaded nanoparticles for the treatment of cancers
12/14/2000WO2000074654A1 Novel preparation and administration form comprising an acid-labile active compound
12/14/2000WO2000074653A1 Oil-core compositions for the sustained release of hydrophobic drugs
12/14/2000WO2000074651A1 Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water
12/14/2000WO2000074650A2 Implantable gel compositions and method of manufacture
12/14/2000WO2000074649A2 Ophthalmic histamine compositions and uses thereof
12/14/2000WO2000074646A2 Novel liposomal vector complexes and their use in gene therapy
12/14/2000WO2000074634A2 Methods and compositions for modulating cell proliferation and cell death
12/14/2000WO2000074632A2 Compositions and methods for alleviating discomforting menstrual symptoms
12/14/2000WO2000074629A2 Composition for implementing a cytotoxic, in particular an antitumoral or antiviral, treatment in a mammal
12/14/2000WO2000074584A1 Devices and methods for treating tissue
12/14/2000WO2000074500A1 Compositions containing creatine in suspension
12/14/2000WO2000074497A1 The combined use of triglycerides containing medium chain fatty acids and exogenous lipolytic enzymes as feed supplements
12/14/2000WO2000074489A1 Stable biocidal compositions
12/14/2000WO2000063208B1 Substituted imidazoles, their preparation and use
12/14/2000WO2000057190A3 Prediction of diabetes impaired wound healing
12/14/2000WO2000053776A3 Human kallikrein-like genes
12/14/2000WO2000053148A3 Methods and compositions for treating erectile dysfunction
12/14/2000WO2000050562A3 Dna encoding snorf25 receptor
12/14/2000WO2000050019A3 USE OF R-ARYL PROPIONIC ACIDS FOR PRODUCING MEDICAMENTS TO TREAT DISEASES IN HUMANS AND ANIMALS, WHEREBY SAID DISEASES CAN BE THERAPEUTICALLY INFLUENCED BY INHIBITING THE ACTIVATION OF NF-λB
12/14/2000WO2000049135A3 Substrate for cell growth
12/14/2000WO2000049040A3 Antimicrobial/endotoxin neutralizing polypeptide
12/14/2000WO2000048554B1 Synergistic antimicrobial skin washing compositions
12/14/2000WO2000047758A3 Methods of making compounds
12/14/2000WO2000047716A3 Fibres for culturing eukaryotic cells
12/14/2000WO2000047568A3 1,2-benzothiazepines for the treatment of hyperlipidemic diseases
12/14/2000WO2000047284A3 Novel use of orexin receptor antagonists
12/14/2000WO2000047231A3 Novel antisense inhibition of rad51
12/14/2000WO2000047229A3 Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules
12/14/2000WO2000046386A3 Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
12/14/2000WO2000046228A3 Pyrrolobenzodiazepine carboxyamide vasopressin agonists
12/14/2000WO2000046225A3 Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists
12/14/2000WO2000046210A3 New process for preparing pesticidal intermediates
12/14/2000WO2000046187A3 Antizyme modulators and their use
12/14/2000WO2000045770A3 Compressed lecithin preparations
12/14/2000WO2000045769A3 Process for extracting polyphenolic antioxidants from purine-containing plants
12/14/2000WO2000044763A3 Compositions for treating inflammatory response
12/14/2000WO2000044408A3 Method of treating demyelinating inflammatory disease using ccr1 antagonists
12/14/2000WO2000044399A3 Treatment of erectile dysfunctions with a c-type natriuretic polypeptide (cnp) as monotherapy or in combination with phosphodiesterase inhibitors
12/14/2000WO2000043032A3 Baff, inhibitors thereof and their use in the modulation of b-cell response
12/14/2000DE19926236A1 Topical spray formulation for applying cortisone or other steroids to the skin, useful for treating acute dermatitis, e.g. sunburn, or irritative skin diseases
12/14/2000DE19926154A1 Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung A process for producing an injectable medicament preparation
12/14/2000DE19925810A1 Anwendung von Verapamil und Verapamilderivaten zur Herstellung von Arzneimitteln mit Glucuronidase hemmender Wirkung Application of verapamil and Verapamilderivaten for producing drugs with glucuronidase inhibiting action
12/14/2000DE19925710A1 Controlled release dosage form for acid-labile active agents, especially proton pump inhibitors, comprising individual units, especially microspheres, of drug in matrix containing fatty alcohol and solid paraffin
12/14/2000DE19924951A1 Prophylaxis of poisoning by organophosphorus choline esterase inhibitors, e.g. insecticides or nerve gases, using desoxypeganine as indirect parasympathicomimetic agent free of undesirable side-effects
12/14/2000CA2751187A1 Use of (-)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid and derivatives thereof for treatment of hyperuricemia
12/14/2000CA2504679A1 Compositions and methods for the treatment of tumor
12/14/2000CA2501815A1 Compositions and methods for the treatment of tumor
12/14/2000CA2390948A1 Cell adhesion-inhibiting antiinflammatory compounds
12/14/2000CA2383828A1 26 human secreted proteins
12/14/2000CA2378735A1 Process for preparing 10,11-methanobenzosuberane derivatives
12/14/2000CA2377385A1 Methods and compositions for modulating cell proliferation and cell death
12/14/2000CA2377369A1 Substituted piperidines as melanocortin-4 receptor agonists
12/14/2000CA2377139A1 Uses of ouabain and ouabain-like molecules in apoptosis related pathologies
12/14/2000CA2376790A1 Siv-based packaging-defficient vectors
12/14/2000CA2376665A1 Novel tet repressor-based transcriptional regulatory proteins
12/14/2000CA2376400A1 Compounds and methods to enhance raav transduction
12/14/2000CA2376314A1 Apoptosis inhibition by adenovirus e3/6.7k
12/14/2000CA2376258A1 Oral preparations of etidronate disodium
12/14/2000CA2376215A1 The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder
12/14/2000CA2376199A1 Use of verapamil and verapamil derivatives for producing medicaments with an inhibiting effect on .beta.-glucuronidase in human tissue
12/14/2000CA2376179A1 Method of treating carcinoma using antibody therapy and ameliorating side effects associated with such therapy
12/14/2000CA2376175A1 Vitamin directed dual targeting therapy
12/14/2000CA2376108A1 Ophthalmic histamine compositions and uses thereof
12/14/2000CA2376076A1 Tricyclic analgesics
12/14/2000CA2376061A1 Pharmaceutical compositions and methods for use
12/14/2000CA2376055A1 Spliceosomal protein and its use
12/14/2000CA2376010A1 Mycolactone and related compounds, compositions and methods of use
12/14/2000CA2376008A1 Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe
12/14/2000CA2375985A1 Indolylpiperidine derivatives as antihistaminic and antiallergic agents
1 ... 6192 6193 6194 6195 6196 6197 6198 6199 6200 6201 6202 6203 6204 6205 6206 6207 6208 6209 6210 6211 6212 ... 7860